United Therapeutics (NASDAQ:UTHR) Price Target Raised to $475.00 at UBS Group

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by stock analysts at UBS Group from $415.00 to $475.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price target would indicate a potential upside of 30.36% from the stock’s current price.

A number of other research firms also recently weighed in on UTHR. Jefferies Financial Group upped their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 30th. HC Wainwright upped their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, TD Cowen boosted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $378.36.

United Therapeutics Price Performance

Shares of UTHR stock traded up $2.05 during trading hours on Wednesday, hitting $364.38. 26,994 shares of the company’s stock were exchanged, compared to its average volume of 198,616. The stock’s 50-day moving average is $370.72 and its 200-day moving average is $351.66. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $417.82. The stock has a market cap of $16.27 billion, a price-to-earnings ratio of 16.00, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period in the prior year, the business earned $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. Equities research analysts forecast that United Therapeutics will post 25.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO James Edgemond sold 7,800 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares of the company’s stock, valued at $2,442,300. This trade represents a 52.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 142,422 shares of company stock valued at $53,498,732 over the last 90 days. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Tri Locum Partners LP purchased a new position in shares of United Therapeutics in the second quarter valued at about $15,959,000. JPMorgan Chase & Co. raised its holdings in United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after buying an additional 50,291 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after buying an additional 123,929 shares during the last quarter. Bridgewater Associates LP increased its position in shares of United Therapeutics by 384.3% during the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock valued at $22,130,000 after acquiring an additional 49,003 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of United Therapeutics by 6.4% in the 3rd quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after purchasing an additional 4,145 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.